Raymond James and Cantor both released bullish notes on uniQure (NASDAQ:QURE) Tuesday in the wake of news that the company ...

UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...

PTC has "pioneered a new approach to treating highly morbid neurologic diseases," said Matthew Klein, the company's chief executive. "I am proud of our team's unwavering commitment to achieve this ...

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the presentation of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Qure (QURE) on Tuesday announced that the company reached an agreement with the FDA on key elements of an Accelerated Approval pathway for ...

It was also under development for the treatment of Rett syndrome, Melas syndrome, Leber’s hereditary optic neuropathy and mitochondrial diseases such as Pearson syndrome, a form of mitochondrial ...

Utreloxastat (PTC-857, EPI-857) is under development for the treatment of adult neurodegenerative diseases including glucocerebrosidase, or GBA, amyotrophic lateral sclerosis and Parkinson’s ...

After hours: December 11 at 4:20:00 PM EST Loading Chart for PTCT ...